AKM Ghulam Muhammad, MBBS
Muhammad joined Cedars-Sinai Regenerative Medicine Institute in July 2012. He is working on accelerating the pace of bench to bed transition of stem cell therapy for neurodegenerative disorders including amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT). In October 2004, at the Cedars-Sinai Gene Therapeutics Research Institute, he spearheaded the gene therapy project for glioblastoma multiforme (GBM), the most common brain tumor and deadliest of all human cancers, which was recently approved by the FDA for a Phase I Clinical Trial (BB-IND 14574; NIH/OBA Protocol 0907-990). Muhammad received his medical degree from the Dhaka University, Bangladesh, and later became a faculty member of the Neurosurgery Department there and established the milestone of stereotactive neurosurgery in Bangladesh by performing the first procedure on a brain tumor patient. As a Japanese Government Monbukagakusho Scholar, Muhammad received his doctorate degree from Osaka University. Subsequently, he was awarded a postdoctoral fellowship under the auspices of The Japan Society for the Promotion of Sciences and contributed to characterizing molecular genetic classification for astrocytic tumors, especially primary and secondary GBM. Muhammad has accumulated research experience for more than 15 years, encompassing a broad base of research in the fields of brain tumors (molecular genetic analysis and development of novel treatment strategies), neuroprotection (selective brain hypothermia) and neurodegenerative disorders, namely ALS, CMT, Parkinson's disease and Alzheimer’s disease. To date, Muhammad has contributed to more than 100 presentations in scientific meetings and has published more than 50 papers.